Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 70 articles:
HTML format
Text format



Single Articles


    May 2019
  1. AFFERI L, Baumeister P, Mordasini L, Mattei A, et al
    Editorial Comment to How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
    Int J Urol. 2019 May 13. doi: 10.1111/iju.14025.
    PubMed     Text format    


  2. BIANCHI L, Schiavina R, Borghesi M, Ceci F, et al
    How does (68) Ga-prostate-specific membrane antigen positron emission tomography/computed tomography impact the management of patients with prostate cancer recurrence after surgery?
    Int J Urol. 2019 May 13. doi: 10.1111/iju.14012.
    PubMed     Text format     Abstract available


  3. YUASA T
    Editorial Comment to Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Int J Urol. 2019 May 12. doi: 10.1111/iju.14018.
    PubMed     Text format    


  4. TANAKA N, Nishimura K, Okajima E, Ina K, et al
    Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.
    Int J Urol. 2019 May 5. doi: 10.1111/iju.14009.
    PubMed     Text format     Abstract available


    March 2019
  5. KOBAYASHI T
    Editorial Comment to Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: regulation of NCAPH by antitumor miR-199a/b-3p.
    Int J Urol. 2019 Mar 4. doi: 10.1111/iju.13919.
    PubMed     Text format    


    February 2019
  6. ARAI T, Kojima S, Yamada Y, Sugawara S, et al
    Micro-ribonucleic acid expression signature of metastatic castration-resistant prostate cancer: Regulation of NCAPH by antitumor miR-199a/b-3p.
    Int J Urol. 2019 Feb 28. doi: 10.1111/iju.13911.
    PubMed     Text format     Abstract available


    December 2018
  7. INOUE T
    Editorial Comment to Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
    Int J Urol. 2018 Dec 21. doi: 10.1111/iju.13887.
    PubMed     Text format    


  8. DING XF, Huang TB, Gao Y, Lu SM, et al
    Permanent (125) I prostate brachytherapy for castration-resistant prostate cancer.
    Int J Urol. 2018 Dec 4. doi: 10.1111/iju.13866.
    PubMed     Text format     Abstract available


    November 2018
  9. INOUE Y, Ushijima S, Shiraishi T, Fujihara A, et al
    Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsy-proven index lesion of prostate cancer.
    Int J Urol. 2018 Nov 28. doi: 10.1111/iju.13857.
    PubMed     Text format    


  10. SHIOTA M, Namitome R, Kobayashi T, Inokuchi J, et al
    Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
    Int J Urol. 2018 Nov 21. doi: 10.1111/iju.13870.
    PubMed     Text format    


  11. HAKOZAKI Y, Matsushima H, Murata T, Masuda T, et al
    Detection rate of clinically significant prostate cancer in magnetic resonance imaging and ultrasonography-fusion transperineal targeted biopsy for lesions with a prostate imaging reporting and data system version 2 score of 3-5.
    Int J Urol. 2018 Nov 21. doi: 10.1111/iju.13842.
    PubMed     Text format     Abstract available


  12. PATEL DN, Chapin BF, Freedland SJ
    Response to Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Nov 20. doi: 10.1111/iju.13861.
    PubMed     Text format    


  13. HAYASHI T, Fujita K, Matsushita M, Hayashi Y, et al
    Metformin inhibits prostate cancer growth induced by a high-fat diet in Pten-deficient model mice.
    Int J Urol. 2018 Nov 20. doi: 10.1111/iju.13847.
    PubMed     Text format    


    October 2018
  14. SAVELLI G, Zaniboni A, Stefanelli A
    Re: Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Int J Urol. 2018 Oct 24. doi: 10.1111/iju.13832.
    PubMed     Text format    


  15. POELAERT F, Schatteman P, Lumen N
    Editorial Comment to Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Oct 22. doi: 10.1111/iju.13837.
    PubMed     Text format    


    September 2018
  16. AFRIANSYAH A, Hamid ARA, Mochtar CA, Umbas R, et al
    Survival analysis and development of a prognostic nomogram for bone-metastatic prostate cancer patients: A single-center experience in Indonesia.
    Int J Urol. 2018 Sep 30. doi: 10.1111/iju.13813.
    PubMed     Text format     Abstract available


  17. YANO A, Kawakami S
    Re: Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018 Sep 30. doi: 10.1111/iju.13809.
    PubMed     Text format    


  18. PATEL DN, Jha S, Howard LE, Amling CL, et al
    Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Sep 25. doi: 10.1111/iju.13806.
    PubMed     Text format     Abstract available


  19. SCHIAVINA R, Chessa F, Borghesi M, Gaudiano C, et al
    State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer.
    Int J Urol. 2018 Sep 20. doi: 10.1111/iju.13797.
    PubMed     Text format     Abstract available


  20. CHOI SY, Ryu J, You D, Hong JH, et al
    Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
    Int J Urol. 2018 Sep 20. doi: 10.1111/iju.13800.
    PubMed     Text format     Abstract available


    August 2018
  21. FUJITA K, Nonomura N
    Urinary biomarkers of prostate cancer.
    Int J Urol. 2018 Aug 21. doi: 10.1111/iju.13734.
    PubMed     Text format     Abstract available


  22. REINSTATLER L, Carmichael D, Austin AM, Goodney PP, et al
    Regional variation in the intensity of prostate cancer care: A study of a large Medicare sample.
    Int J Urol. 2018 Aug 13. doi: 10.1111/iju.13775.
    PubMed     Text format    


    July 2018
  23. KANAO K, Kajikawa K, Kobayashi I, Morinaga S, et al
    Impact of a novel biopsy instrument with a 25-mm side-notch needle on the detection of prostate cancer in transrectal biopsy.
    Int J Urol. 2018 Jul 18. doi: 10.1111/iju.13722.
    PubMed     Text format     Abstract available


    June 2018
  24. SAKAMOTO S
    Editorial Comment to Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018;25:531-532.
    PubMed     Text format    


    May 2018
  25. YANO A, Arai Y, Kitayama S, Otsuka Y, et al
    Effect of zoledronic acid dosing every 3 months in patients with prostate cancer with skeletal metastases: A multicenter prospective exploratory study with matched historical controls.
    Int J Urol. 2018 May 14. doi: 10.1111/iju.13703.
    PubMed     Text format    


  26. CHEN PY, Chiang PH, Liu YY, Chuang YC, et al
    Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
    Int J Urol. 2018 May 13. doi: 10.1111/iju.13581.
    PubMed     Text format     Abstract available


  27. KIMURA T, Egawa S
    Epidemiology of prostate cancer in Asian countries.
    Int J Urol. 2018 May 8. doi: 10.1111/iju.13593.
    PubMed     Text format     Abstract available


  28. SAKAMOTO S
    Editorial Comment to Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018;25:403-404.
    PubMed     Text format    


    April 2018
  29. MITSUI Y
    Editorial Comment to Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Sca
    Int J Urol. 2018 Apr 16. doi: 10.1111/iju.13582.
    PubMed     Text format    


  30. MEARINI L
    Editorial Comment to Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13575.
    PubMed     Text format    


  31. KITAGAWA Y
    Editorial Comment to Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13578.
    PubMed     Text format    


  32. IZUMI K
    Editorial Comment to Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13572.
    PubMed     Text format    


  33. TAKAMOTO A, Tanimoto R, Bekku K, Araki M, et al
    Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer.
    Int J Urol. 2018 Apr 12. doi: 10.1111/iju.13555.
    PubMed     Text format     Abstract available


  34. NAKAJIMA K, Kaneko G, Takahashi S, Matsuyama H, et al
    Role of bone scan index in the prognosis and effects of therapy on prostate cancer with bone metastasis: Study design and rationale for the multicenter Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index (PROSTAT-BSI)
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13556.
    PubMed     Text format     Abstract available


  35. HASHIMOTO T, Ohori M, Shimodaira K, Kaburaki N, et al
    Prostate-specific antigen screening impacts on biochemical recurrence in patients with clinically localized prostate cancer.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13563.
    PubMed     Text format     Abstract available


  36. BIANCHI L, Schiavina R, Borghesi M, Bianchi FM, et al
    Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database.
    Int J Urol. 2018 Apr 6. doi: 10.1111/iju.13565.
    PubMed     Text format     Abstract available


    March 2018
  37. OKIHARA K
    Editorial Comment to Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Mar 25. doi: 10.1111/iju.13570.
    PubMed     Text format    


  38. TILKI D, Pompe RS, Bandini M, Marchioni M, et al
    Local treatment for metastatic prostate cancer: A systematic review.
    Int J Urol. 2018 Mar 23. doi: 10.1111/iju.13535.
    PubMed     Text format     Abstract available


  39. HAKARIYA T, Shida Y, Tsurusaki T, Watanabe J, et al
    Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
    Int J Urol. 2018 Mar 8. doi: 10.1111/iju.13542.
    PubMed     Text format     Abstract available


  40. ALBERTS AR, Roobol MJ
    Editorial Comment to Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2018;25:277.
    PubMed     Text format    


    February 2018
  41. KIKKAWA K, Iba A, Kohjimoto Y, Noda Y, et al
    Impact of age on quality of life in patients with localized prostate cancer treated with high-dose rate brachytherapy combined with external beam radiotherapy.
    Int J Urol. 2018 Feb 4. doi: 10.1111/iju.13530.
    PubMed     Text format     Abstract available


  42. AKAMATSU S, Inoue T, Ogawa O, Gleave ME, et al
    Clinical and molecular features of treatment-related neuroendocrine prostate cancer.
    Int J Urol. 2018 Feb 3. doi: 10.1111/iju.13526.
    PubMed     Text format     Abstract available


    January 2018
  43. BEGEMANN D, Anastos H, Kyprianou N
    Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13505.
    PubMed     Text format     Abstract available


  44. SAKAMOTO S
    Editorial Comment to Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Int J Urol. 2018 Jan 17. doi: 10.1111/iju.13510.
    PubMed     Text format    


  45. TAKEI A, Sakamoto S, Wakai K, Tamura T, et al
    Duration of androgen deprivation therapy and nadir of testosterone at 20 ng/dL predict testosterone recovery to supracastrate level in prostate cancer patients who received external beam radiotherapy.
    Int J Urol. 2018 Jan 11. doi: 10.1111/iju.13521.
    PubMed     Text format     Abstract available


  46. MURATA Y, Tatsugami K, Yoshikawa M, Hamaguchi M, et al
    Predictive factors of biochemical recurrence after radical prostatectomy for high-risk prostate cancer.
    Int J Urol. 2018 Jan 8. doi: 10.1111/iju.13514.
    PubMed     Text format     Abstract available


    December 2017
  47. KOMURA K, Sweeney CJ, Inamoto T, Ibuki N, et al
    Current treatment strategies for advanced prostate cancer.
    Int J Urol. 2017 Dec 20. doi: 10.1111/iju.13512.
    PubMed     Text format     Abstract available


  48. NEUPANE S, Steyerberg E, Raitanen J, Talala K, et al
    Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
    Int J Urol. 2017 Dec 10. doi: 10.1111/iju.13508.
    PubMed     Text format     Abstract available


    November 2017
  49. NAKANO M, Araki H, Ohtakara K, Tanaka H, et al
    Significance of total colonoscopy screening before definitive radiotherapy for prostate cancer on the detection of anorectocolonic disease requiring intervention in advance.
    Int J Urol. 2017 Nov 23. doi: 10.1111/iju.13494.
    PubMed     Text format    


    October 2017
  50. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Improved survival of men with metastatic prostate cancer treated with androgen deprivation therapy plus radiotherapy to the prostate.
    Int J Urol. 2017 Oct 23. doi: 10.1111/iju.13479.
    PubMed     Text format    


  51. MITSUZUKA K, Arai Y
    Metabolic changes in patients with prostate cancer during androgen deprivation therapy.
    Int J Urol. 2017 Oct 20. doi: 10.1111/iju.13473.
    PubMed     Text format     Abstract available


    September 2017
  52. SAIKA T, Miura N, Fukumoto T, Yanagihara Y, et al
    Role of robot-assisted radical prostatectomy in locally advanced prostate cancer.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13441.
    PubMed     Text format     Abstract available


  53. PEREIRA-AZEVEDO N, Braga I, Verbeek JF, Osorio L, et al
    Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
    Int J Urol. 2017 Sep 13. doi: 10.1111/iju.13442.
    PubMed     Text format     Abstract available


  54. YANO A, Kagawa M, Takeshita H, Okada Y, et al
    Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naive prostate cancer with skeletal metastases.
    Int J Urol. 2017 Sep 11. doi: 10.1111/iju.13445.
    PubMed     Text format    


    August 2017
  55. SAKAMOTO S
    Editorial Comment to Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
    Int J Urol. 2017 Aug 20. doi: 10.1111/iju.13436.
    PubMed     Text format    


  56. SAKAMOTO S
    Editorial Comment to Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.
    Int J Urol. 2017 Aug 6. doi: 10.1111/iju.13433.
    PubMed     Text format    


    July 2017
  57. DINH KT, Yang DD, Nead KT, Reznor G, et al
    Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer.
    Int J Urol. 2017 Jul 22. doi: 10.1111/iju.13409.
    PubMed     Text format     Abstract available


  58. KAKEHI Y, Sugimoto M, Taoka R
    Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
    Int J Urol. 2017 Jul 1. doi: 10.1111/iju.13380.
    PubMed     Text format     Abstract available


    June 2017
  59. NOGUCHI M, Koga N, Igawa T, Itoh K, et al
    Clinical development of immunotherapy for prostate cancer.
    Int J Urol. 2017 Jun 21. doi: 10.1111/iju.13397.
    PubMed     Text format     Abstract available


  60. MCGINLEY KF, Sun X, Howard LE, Aronson WJ, et al
    Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.
    Int J Urol. 2017 Jun 6. doi: 10.1111/iju.13387.
    PubMed     Text format     Abstract available


  61. MIZOKAMI A, Kadono Y, Kitagawa Y, Izumi K, et al
    Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Int J Urol. 2017 Jun 3. doi: 10.1111/iju.13372.
    PubMed     Text format     Abstract available


    May 2017
  62. ENATSU N
    Editorial Comment to Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Impl
    Int J Urol. 2017 May 31. doi: 10.1111/iju.13383.
    PubMed     Text format    


  63. NAKAJIMA K, Edenbrandt L, Mizokami A
    Bone scan index: A new biomarker of bone metastasis in patients with prostate cancer.
    Int J Urol. 2017 May 26. doi: 10.1111/iju.13386.
    PubMed     Text format     Abstract available


  64. MITSUZUKA K
    Editorial comment to Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 May 21. doi: 10.1111/iju.13379.
    PubMed     Text format    


    April 2017
  65. TERADA N, Maughan BL, Akamatsu S, Kobayashi T, et al
    Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13346.
    PubMed     Text format     Abstract available


  66. OKIHARA K, Yorozu A, Saito S, Tanaka N, et al
    Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13358.
    PubMed     Text format     Abstract available


  67. NISHIKAWA M, Miyake H, Fujisawa M
    Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy.
    Int J Urol. 2017 Apr 18. doi: 10.1111/iju.13352.
    PubMed     Text format     Abstract available


    March 2017
  68. NARAYAN VM, Konety BR, Warlick C
    Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.
    Int J Urol. 2017 Mar 27. doi: 10.1111/iju.13326.
    PubMed     Text format     Abstract available


    September 2016
  69. KAMADA S
    Editorial Comment to Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy.
    Int J Urol. 2016 Sep 7. doi: 10.1111/iju.13195.
    PubMed     Text format    


    August 2016
  70. MOROTE J, Comas I, Planas J, Celma A, et al
    Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy.
    Int J Urol. 2016 Aug 3. doi: 10.1111/iju.13180.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: